Humana $HUM Stock: Overvalued or Undervalued?

Humana ($HUM+WL) has captured investor attention following an earnings beat and enhancements in care quality, alongside initiatives for caregiver retention and leadership in its Medicaid unit. This has coincided with robust share price performance, including a 27.5% return over the past 90 days and a 47.1% year-to-date gain, although the three-year total shareholder return remains down 17.7%.

Differing perspectives on Humana's valuation persist. One narrative positions the stock as 26.2% overvalued, estimating fair value at $308.33 against a recent closing price of $389.05, based on a 7.1% discount rate and long-term forecasts. This view factors in growth in value-based models and strategic capital allocation for primary care expansion.

Conversely, the Simply Wall St Discounted Cash Flow (DCF) model suggests a different outlook, indicating Humana trades at a 61.2% discount to an estimated future cash flow value of $1,001.49. This divergence raises questions about whether analysts are being overly cautious or if the DCF model is assuming excessively optimistic long-term cash generation.

Key risks to Humana's narrative include uncertainties surrounding Medicare Advantage Stars ratings and medical cost trends, which could impact margin and earnings assumptions. Investors are left to analyze these conflicting valuation signals amid ongoing operational developments within the healthcare provider.